This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Analysts Estimate Bruker (BRKR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bruker Rides on Nano and MALDI Launches Despite Margin Debacle
by Zacks Equity Research
Bruker (BRKR) has several Bruker NANO products that are being assembled and tested in Malaysia.
Bruker's Buyout of Canopy Biosciences Enhances Portfolio
by Zacks Equity Research
Bruker (BRKR) expands its multi-dimensional immune profiling by adding ChipCytometry tools via the acquisition of Canopy Biosciences.
The Zacks Analyst Blog Highlights: Mettler-Toledo, PerkinElmer, Waters and Bruker
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mettler-Toledo, PerkinElmer, Waters and Bruker
Bruker Banks on Strategic Innovation Amid Coronavirus Crisis
by Zacks Equity Research
At Bruker's (BRKR) Germany campus, the company currently offers a pilot COVID-19 at work testing program for its factory workforce.
4 Stocks to Watch on Rising Demand for Scientific Instruments
by Aniruddha Ganguly
The Zacks Instruments - Scientific industry is gaining from strong life science, pharmaceutical and academic end-market demand. Industry participants MTD, PKI, WAT and BRKR are set to gain from rising healthcare spending and exposure to developing economies like China and India.
Why Is Bruker (BRKR) Down 4.5% Since Last Earnings Report?
by Zacks Equity Research
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bruker Rides on MALDI Launches Amid Coronavirus-Led Crisis
by Zacks Equity Research
For higher specific detection of the SARS-CoV-2 virus, Bruker (BRKR) launches luoroType SARS-CoV-2 plus next-generation 6-plex PCR assay.
Bruker (BRKR) Q2 Earnings Surpass Estimates, Margins Fall
by Zacks Equity Research
Bruker's (BRKR) second-quarter 2020 results reflect dismal performance by all segments and geographies due to coronavirus-led business disruptions.
Badger Meter (BMI) Q2 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Thanks to COVID-19 related uncertainties, Badger Meter's (BMI) second-quarter 2020 earnings and revenues decline year over year with lower demand across various end-markets.
Why Is Bruker (BRKR) Up 7.5% Since Last Earnings Report?
by Zacks Equity Research
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bruker Rides on PCI Sales, Coronavirus-Led Supply Issues Hurt
by Zacks Equity Research
Bruker (BRKR) expects a rise in sales within life science, biopharma and basic medical research, as well as in infectious disease diagnostics due to the pandemic.
New Strong Sell Stocks for May 28th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Bruker (BRKR) Q1 Earnings Miss Estimates, Guidance Suspended
by Zacks Equity Research
Bruker's (BRKR) first-quarter 2020 results reflect dismal performance by all segments and geographies due to coronavirus-led business disruptions.
Bruker (BRKR) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of -36.36% and -1.25%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Bruker (BRKR) Reports Next Week: What You Should Expect
by Zacks Equity Research
Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Bruker (BRKR) Down 8.1% Since Last Earnings Report?
by Zacks Equity Research
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for April 6th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Bruker (BRKR) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Bruker's (BRKR) fourth-quarter 2019 results reflect strong performances by the majority of its segments and geographies.
Bruker Inks Deal to Distribute Coronavirus Detection Test
by Zacks Equity Research
The agreement would make Bruker (BRKR) a key player in coronavirus diagnosis.
Bruker (BRKR) Stock Rises on Strong Preliminary Q4 Show
by Zacks Equity Research
Bruker's (BRKR) revenue growth is expected to beat expectations for the fourth quarter and 2019.
What's in the Cards for MercadoLibre's (MELI) Q4 Earnings?
by Zacks Equity Research
MercadoLibre's (MELI) fourth-quarter results are likely to have benefited from its fintech and logistics offerings. However, rising expenses remained a concern.
Akamai (AKAM) Gears Up for Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Akamai's (AKAM) fourth-quarter results are expected to reflect solid adoption of Kona Site Defender and Prolexic Solutions.
Bruker (BRKR) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Bruker (BRKR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FUJIFILM (FUJIY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
FUJIFILM's (FUJIY) third-quarter fiscal 2020 results are expected to reflect robust performance of the Healthcare business.